Next Article in Journal
Staphylococcus aureus Infection and Persistence in Chronic Rhinosinusitis: Focus on Leukocidin ED
Previous Article in Journal
Covariation of Ergot Severity and Alkaloid Content Measured by HPLC and One ELISA Method in Inoculated Winter Rye across Three Isolates and Three European Countries
Open AccessArticle

Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA

Department of Neurology, University of Düsseldorf, Moorenstraße 5, D-40225 Düsseldorf, Germany
*
Author to whom correspondence should be addressed.
Toxins 2020, 12(11), 677; https://doi.org/10.3390/toxins12110677
Received: 1 September 2020 / Revised: 24 October 2020 / Accepted: 25 October 2020 / Published: 27 October 2020
(This article belongs to the Section Bacterial Toxins)
Botulinum toxin type B (BoNT/B) has been recommended as an alternative for patients who have become resistant to botulinum toxin type A (BoNT/A). This study aimed to compare the clinical effect, within a patient, of four injections with low doses of rimabotulinumtoxinB with the effect of the preceding abobotulinumtoxinA (aboBoNT/A) injections. In 17 patients with cervical dystonia (CD) who had become resistant to aboBoNT/A, the clinical effect of the first four rimabotulinumtoxinB (rimaBoNT/B) injections was compared to the effect of the first four aboBoNT/A injections using a global assessment scale and the TSUI score. After the first two BoNT/B injections, all 17 patients responded well and to a similar extent as to the first two BoNT/A injections, but with more side effects such as dry mouth and constipation. After the next BoNT/B injection, the improvement started to decline. The response to the fourth BoNT/B injection was significant (p < 0.048) lower than the fourth BoNT/A injection. Only three patients developed a complete secondary treatment failure (CSTF) and five patients a partial secondary treatment failure (PSTF) after four BoNT/B injections. In nine patients, the usual response persisted. With the use of low rimaBoNT/B doses, the induction of CSTF and PSTF to BoNT/B could not be avoided but was delayed in comparison to the use of higher doses. In contrast to aboBoNT/A injections, PSTF and CSTF occurred much earlier, although low doses of rimaBoNT/B had been applied. View Full-Text
Keywords: secondary non-response; antibody induction; botulinum toxin type A; botulinum toxin type B; cervical dystonia secondary non-response; antibody induction; botulinum toxin type A; botulinum toxin type B; cervical dystonia
Show Figures

Figure 1

MDPI and ACS Style

Hefter, H.; Samadzadeh, S.; Moll, M. Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA. Toxins 2020, 12, 677. https://doi.org/10.3390/toxins12110677

AMA Style

Hefter H, Samadzadeh S, Moll M. Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA. Toxins. 2020; 12(11):677. https://doi.org/10.3390/toxins12110677

Chicago/Turabian Style

Hefter, Harald; Samadzadeh, Sara; Moll, Marek. 2020. "Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA" Toxins 12, no. 11: 677. https://doi.org/10.3390/toxins12110677

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop